Why Umbilical Cord Tissue: The Wharton's Jelly Source

What Is Wharton's Jelly

Wharton's Jelly is the gelatinous connective tissue that surrounds and protects the blood vessels of the umbilical cord. It is a mucous connective tissue, rich in hyaluronic acid and collagen, that has been recognized as a source of mesenchymal stromal cells (MSCs) since the tissue was first characterized for this purpose in the early 1990s. Umbilical cord tissue, including Wharton's Jelly, is collected after a full-term birth from tissue that is otherwise discarded. Collection does not require an invasive procedure on a living donor.

This is a meaningfully different starting material than the source tissues used by many other manufacturers. Understanding the tissue source matters for the same reason that culture geometry and media composition matter: it is an upstream variable that determines what the resulting cell population can secrete.

Source Tissue: Umbilical Cord vs. Adipose vs. Amniotic vs. Bone Marrow

MSCs used in exosome manufacturing are isolated from several different tissue types, and the published literature does not treat these sources as interchangeable. Some general, well-established distinctions:

Adult-tissue MSCs (adipose, bone marrow) come from donors who have accumulated years of environmental exposure, and adult MSC populations are documented in the broader stem cell literature to show donor-age-associated and tissue-of-origin-associated variability in proliferative capacity and secretory profile. Perinatal-tissue sources, including umbilical cord tissue and amniotic tissue, are collected from a single, standardized developmental timepoint. Cord tissue and amniotic tissue are not the same source, they come from different structures of the perinatal unit and are not interchangeable in the literature, which is why the studies below specify umbilical cord tissue (Wharton's Jelly) rather than perinatal tissue generally.

Protein-Level Evidence: Umbilical Cord Tissue MSC Secretome in 3D vs. 2D

Santos et al. (2015) directly compared the secretome of human umbilical cord tissue-derived MSCs (referred to in the paper as UCX cells) grown as 3D spheroids against the same cells grown in conventional 2D monolayer, using matched cell numbers, conditioning volume, and conditioning time. This is a protein-level comparison: secreted factors were measured directly in the conditioned medium by bead-based immunoassay, not inferred from gene expression.^[1]

The KGF result matters for how this evidence should be read: 3D culture does not uniformly increase every secreted factor. The paper's finding is that 3D geometry changes the secretome of umbilical cord tissue MSCs in a factor-specific way, with several major growth factors substantially elevated. This is protein-level evidence specific to umbilical cord tissue MSCs, not a study using adipose, bone marrow, or amniotic cells.

Gene Expression Evidence: Wharton's Jelly MSCs in Scaffold-Free 3D Culture

Thakur et al. (2022) examined Wharton's Jelly MSCs specifically, cultured in scaffold-free 3D conditions.^[2] The reported increases in VEGF, IL-10, LIF, ANG1, and IDO in this study were measured primarily by RT-qPCR, meaning they reflect gene transcription, not directly measured secreted protein concentration in the conditioned medium. Transcription and secretion are related but not identical measurements, and this study should be read as gene-expression evidence of the same general pattern documented at the protein level by Santos et al. above, not as a second protein-level confirmation of the same numbers.

Yield Evidence: Exosome Output from 3D-Cultured Umbilical Cord Tissue MSCs

Two independent groups have reported substantially higher exosome yield per cell from 3D-cultured umbilical cord tissue MSCs relative to 2D monolayer culture of the same cell type:

• Yan and Wu (2020) cultured umbilical cord MSCs in a hollow-fiber bioreactor and reported improved exosome yield along with improved activity in osteochondral regeneration assays, relative to matched 2D production.^[3]
• Haraszti et al. (2018) reported higher exosome yield and improved functional activity from 3D-cultured, tangential-flow-filtration-isolated MSC preparations relative to 2D culture, using human umbilical cord-derived MSCs.^[4] This is the same study cited on the Why 3D Culture page for its yield data; the cell source for that study is umbilical cord tissue, stated explicitly here because the source tissue is this page's specific subject.

What This Means for Evaluating a Preparation

Culture geometry (3D vs. 2D, see Why 3D Culture) and media composition (xenofree vs. serum-containing, see Xenofree Manufacturing) are manufacturing variables that apply on top of whatever cell population is being cultured. Source tissue is the variable underneath both of those. A 3D, xenofree manufacturing process applied to umbilical cord tissue MSCs is not the same starting point as the identical process applied to adipose or bone marrow MSCs, because the published literature documents differences in secretory profile that trace back to the tissue of origin, independent of downstream processing choices.

When reviewing published clinical or in-vitro evidence for any exosome or secretome product, it is worth checking whether the cited studies used the same source tissue as the product itself. A study demonstrating a clinical outcome with adipose-derived exosomes is evidence about adipose-derived exosomes. It does not by itself establish the same outcome for a preparation manufactured from umbilical cord tissue. The reverse is equally true. This is why the studies on this page specify umbilical cord tissue (Wharton's Jelly) by name, and why other pages on this site that cite studies using a different source tissue note that difference explicitly.